Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib in relapsed or refractory follicular lymphoma
ChiCTR2000032427Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in follicular lymphoma (FL), sponsored by Ruijin Hospital. Primary endpoint: Overall response rate by independent review committee using Cheson 2007 criteria. Planned start May 2020; status: not yet recruiting.
02
Drugs
duvelisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2000032427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032427.